Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC study reveals breed dispositions for rare adrenal tumour
Phaeochromocytoma can be life-threatenng for dogs.

Miniature schnauzers among those more likely to receive diagnosis.

The Royal Veterinary College (RVC) has shared new insights into the risk factors of a rare adrenal tumour in dogs.

Researchers analysed health records from dogs with a phaeochromacytoma diagnosis to assess breed disposition, and other risk factors, of the life-threatening condition.

Phaeochromocytoma, which occurs in both dogs and humans, is a rare tumour which develops in the adrenal medulla. It results in the over-production of hormones, including ephinephrine and norephinephrine, due to cardiac complications.

Among the clinical signs are hypertension, collapse, an increased heart rate, and an irregular heart rate. These can be intermittent and can be easily mistaken for hormonal, neurological and cardiovascular conditions.

Diagnostic biochemical tests for the tumour are relatively new to veterinary practices, and there are limited reports of the frequency of the condition.

To improve understanding, researchers analysed RVC VetCompass Programme’s health records for phaeochromocytoma diagnosis in dogs. This included annual prevalence and frequency, as well as the demographic risk factors for the tumour.

The findings revealed an annual incidence risk of 1 per 100,000 dogs – statistics 25 times higher than human phaeochromocytoma.

There were several dog breeds which had a predisposition to the adrenal tumour. This included the soft-coated wheaten terrier (30.9 times more likely), German pointer (11 times more likely), and the miniature schnauzer (4.7 times more likely).

Terrier breeds were identified as having an increased risk of phaeochromocytoma, as were breeds that are predisposed to endocrine tumours.

Other risk factors included being a neutered male and aged between nine and 15 years, with such dogs more likely to receive the diagnosis than entire males and those under the age of nine..

Floryne Buishand, senior lecturer in small animal soft tissue surgery at the RVC, said: “The findings of our study are important for both veterinary and human surgeons and scientists.

“For the first time, we demonstrated that the overall incidence of phaeochromocytoma in dogs is up to 25 times higher compared to the incidence of phaeochromocytoma in humans.

“This underpins the value of spontaneous canine phaeochromocytoma as a translational study model for human phaeochromocytoma because canine phaeochromocytoma samples are more readily available for molecular studies, unlike human phaeochromocytoma samples.” 

The full study can be found in the journal PLoS One

Image © Royal Veterinary College

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.